Skip to Main Content

Good morning, everyone, welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and teleconferences has predictably returned. But what can you do? The world keeps spinning, wobbly as it may appear. So to cope, we are firing up our trusty coffee kettle and brewing a few cups of stimulation. Support your neurons today. Meanwhile, here are a few tidbits to get you started. Hope your day goes well and, of course, do keep in touch. We appreciate your tips and insights. …

Regeneron Pharmaceuticals (REGN) will pay $800 million to Alnylam Pharmaceuticals (ALNY) to leverage its gene silencing technique for developing new therapies and become its exclusive partner for new drugs focused on the central nervous system or the eye, STAT reports. The collaboration will combine Regeneron’s genetic research with Alnylam’s technology, which centers on RNA interference, or RNAi, technology that uses small bits of the chemical messenger RNA to block genetic messages from cells. Regeneron and Sanofi (SNY) are ending most of an RNAi pact, PMLive notes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!